FIG's Strategic Investment in Elitepharm Brings AI Innovations to Nutraceuticals
On February 17, 2025, Freedom International Group (FIG) announced a significant strategic investment in Elitepharm Laboratoires, marking a pivotal move towards enhancing the nutraceutical industry. With this investment, FIG has established itself as one of the primary shareholders in Elitepharm, a key player in France dedicated to formulating and producing custom dietary supplements.
Narek Sirakanyan, FIG's President and CEO, emphasized the importance of this investment, stating it represents a substantial step forward for their industrial growth. "We are integrating our AI-driven software to improve dietary supplement formulas, thereby positioning ourselves competitively within a booming market," he noted. FIG, a technology, finance, health, and wellness investment firm, oversees assets exceeding €2.5 billion. This background allows FIG to leverage its technological expertise to advance Elitepharm’s product development.
Elitepharm is renowned for its comprehensive solutions in the field of dietary supplements, ranging from research and development to manufacturing private-label products in both small and large batches. The company's operational flexibility and dedication to quality have made it a recognized leader in France’s nutraceutical sector.
"By investing in Elitepharm, we are not only bolstering our presence in the health and wellness industry, but also capitalizing on France’s potential as a leading hub for dietary supplement production. Its proximity to active ingredient suppliers, stringent industry regulations, and advanced freezing technology makes it an optimal location for our operations," Sirakanyan elaborated.
This alliance, formalized between Sirakanyan and Gérard Strauch, President and CEO of Elitepharm, represents a strategic integration, as FIG’s Project V produces around 40 different products at Elitepharm facilities. With ambitious plans, Elitepharm aims to grow its revenue to €50 million by 2029, leveraging FIG's prowess to accelerate its industrialization and commercial development.
Currently producing approximately 25 million capsules monthly, Elitepharm is set to double this output to meet escalating international demand. The shared vision of innovation and industrial excellence acts as the driving force behind this collaboration. Strauch has cultivated Elitepharm into a company recognized for its scientific rigor and ability to anticipate market trends, ensuring it is well-positioned for future growth.
The investment from FIG will expedite Elitepharm's strategic initiatives, including enhancing existing facilities and acquiring new production sites to boost capacity. They also plan to oversee the entire value chain of their operations, which involves investing in organic farming to secure quality raw materials. Expanding their private-label brand portfolio is another priority, involving further collaboration with industry experts to stay ahead of market trends.
Sirakanyan remarked, "Our acquisition of Elitepharm is a crucial move in our vertical integration strategy, which will continue by investing in farms growing organic active ingredients for Elitepharm’s supply chain." This ambition looks to establish Elitepharm as a leading player in Europe, underpinned by shared strategic outlooks on innovation and industrial capacity. Strauch confidently proclaimed, "FIG's investment will enable us to take vital steps towards positioning Elitepharm as a significant name in Europe. We are committed to sustainable health and wellness industrial practices through this alliance."
With a strong foundation for industrial excellence, FIG and Elitepharm together embark on a journey to redefine the nutraceutical landscape across Europe, firmly establishing themselves as leaders committed to health and wellness advancements.
For media inquiries, please contact Raffaello Porro at +393351015456.
Narek Sirakanyan, FIG's President and CEO, emphasized the importance of this investment, stating it represents a substantial step forward for their industrial growth. "We are integrating our AI-driven software to improve dietary supplement formulas, thereby positioning ourselves competitively within a booming market," he noted. FIG, a technology, finance, health, and wellness investment firm, oversees assets exceeding €2.5 billion. This background allows FIG to leverage its technological expertise to advance Elitepharm’s product development.
Elitepharm is renowned for its comprehensive solutions in the field of dietary supplements, ranging from research and development to manufacturing private-label products in both small and large batches. The company's operational flexibility and dedication to quality have made it a recognized leader in France’s nutraceutical sector.
"By investing in Elitepharm, we are not only bolstering our presence in the health and wellness industry, but also capitalizing on France’s potential as a leading hub for dietary supplement production. Its proximity to active ingredient suppliers, stringent industry regulations, and advanced freezing technology makes it an optimal location for our operations," Sirakanyan elaborated.
This alliance, formalized between Sirakanyan and Gérard Strauch, President and CEO of Elitepharm, represents a strategic integration, as FIG’s Project V produces around 40 different products at Elitepharm facilities. With ambitious plans, Elitepharm aims to grow its revenue to €50 million by 2029, leveraging FIG's prowess to accelerate its industrialization and commercial development.
Currently producing approximately 25 million capsules monthly, Elitepharm is set to double this output to meet escalating international demand. The shared vision of innovation and industrial excellence acts as the driving force behind this collaboration. Strauch has cultivated Elitepharm into a company recognized for its scientific rigor and ability to anticipate market trends, ensuring it is well-positioned for future growth.
The investment from FIG will expedite Elitepharm's strategic initiatives, including enhancing existing facilities and acquiring new production sites to boost capacity. They also plan to oversee the entire value chain of their operations, which involves investing in organic farming to secure quality raw materials. Expanding their private-label brand portfolio is another priority, involving further collaboration with industry experts to stay ahead of market trends.
Sirakanyan remarked, "Our acquisition of Elitepharm is a crucial move in our vertical integration strategy, which will continue by investing in farms growing organic active ingredients for Elitepharm’s supply chain." This ambition looks to establish Elitepharm as a leading player in Europe, underpinned by shared strategic outlooks on innovation and industrial capacity. Strauch confidently proclaimed, "FIG's investment will enable us to take vital steps towards positioning Elitepharm as a significant name in Europe. We are committed to sustainable health and wellness industrial practices through this alliance."
With a strong foundation for industrial excellence, FIG and Elitepharm together embark on a journey to redefine the nutraceutical landscape across Europe, firmly establishing themselves as leaders committed to health and wellness advancements.
For media inquiries, please contact Raffaello Porro at +393351015456.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.